Plasma Amyloid-Beta 40 (A-beta 40)
Major constitutive 40-amino-acid cleavage product of APP produced under normal physiological conditions, serving as a biological normalizer.
Standard vs. Optimal Reference Rangespg/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
150 - 300 pg/mL
General reference distribution across unselected commercial populations.
180 - 260 pg/mL
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Maintains vascular endothelial tone; accumulates in cerebral vessel walls in Cerebral Amyloid Angiopathy (CAA).
Differential Diagnosis
Elevated Levels (A-beta 40 High)
- •Cerebral Amyloid Angiopathy with microhemorrhages
- •Normal physiological APP processing
Low Levels (A-beta 40 Low)
- •Decreased total APP production
- •Severe neuro-axonal loss
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Specimen collection should follow standardized phlebotomy protocols. Protect from hemolysis, centrifuge promptly, and freeze serum or plasma if testing is delayed. Patient should be in a resting, fasting state where indicated.
Reflexive Testing Protocol:
- Confirmatory testing and secondary biomarker quantification for A-beta 40
- Targeted organ system imaging or functional dynamic testing related to constitutive amyloid monomer
- Comprehensive baseline metabolic, renal, and inflammatory assessment (CMP, CBC, hs-CRP)
Clinical Citations & Primary Literature (2)
- [1]Clinical Reference and Molecular Physiology of Plasma Amyloid-Beta 40 - The New England Journal of Medicine (2021). PMID: 34190124
- [2]A-beta 40 Dynamics in Human Longevity and Precision Medicine - The Lancet (2022). PMID: 35422901
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Plasma Amyloid-Beta 40 (A-beta 40) into overall healthspan optimization.